Standard pacing therapy regulates heart pumping as well as costly tailored methods

Standard pacing therapy regulates heart pumping as well as costly tailored methods
Abstract 21780

Study Highlights:

•Standard cardiac resynchronization therapy (CRT), in which a special device tunes the heart’s rhythm, worked as well as more costly and time-consuming methods in a new study.
•Standard CRT only works in about 70 percent of patients, so researchers sought ways to improve its effectiveness.
•All patient groups improved, but researchers found no significant differences overall between the standard method and two more complex methods of optimizing the CRT device.
•In a secondary subgroup analysis, women did appear to benefit from optimizing the device.


CHICAGO, Nov. 15, 2010 – Standard cardiac resynchronization therapy (CRT) is as effective as two other methods that regulate the time interval between the squeezing of the heart’s upper and lower chambers, according to late-breaking clinical trial results presented at the American Heart Association’s Scientific Sessions 2010.

The SMART AV trial included 1,014 heart failure patients (68 percent male, average age 66) at 100 sites in the United States and Europe. Each patient had suboptimal atrioventricular (AV) interval delay, a condition in which the timing between the constrictions of the heart’s upper (atria) and lower (ventricles) chambers is askew by milliseconds.

Physicians have treated the problem with cardiac resynchronization therapy, in which a special pacemaker-defibrillator tunes the heart’s rhythm to make the heart’s walls contract more uniformly and effectively.

In the study, researchers randomized 980 of the patients to one of the three therapies:

•The standard therapy of a pre-set AV interval of 120 milliseconds for the time delay between atrial and ventricle constrictions;
•Echocardiography-customization of the AV interval determined after device implantation by an ultrasound examination of blood flow into the patient’s left ventricle and across the mitral valve (as recommended by the American Society of Echocardiography);
•AV optimization by the SmartDelay™ algorithm, a technique derived from hemodynamic laboratory studies in humans.
The primary endpoint was the volume of the left ventricle, the heart’s main pumping chamber, at the end of contraction. Its secondary endpoints were heart function; patients’ self-reported quality of life; improvement in walking for six minutes; the left ventricle’s volume at the end of relaxation; and its squeezing force while ejecting blood.

At the end of the six-month trial, researchers found no significant difference in the primary or any of the secondary endpoints among the three patient groups.

“These conclusions are quite important,” said Kenneth A. Ellenbogen, M.D., lead author of the study and Kontos professor of cardiology and department chairman at the Virginia Commonwealth University School of Medicine in Richmond. “Routine AV optimization is not worth the time, the cost, or the effort because there is no detriment to using a device as it is programmed off the shelf.”

However, he said that in patients who do not respond to this therapy, some technique for optimizing the AV interval may be useful.

“We know CRT is tremendously effective,” Ellenbogen said. “It can decrease mortality and improve quality of life. It can increase heart muscle function and the amount of blood the heart pumps. In people with enlarged hearts, the size of the ventricular pumping chamber of the heart actually shrinks.”

However, only about 70 percent of patients respond to CRT. So researchers have sought to improve the therapy by focusing on how to best resynchronize the heart’s upper and lower contractions.

In a subanalysis of the women in the study, the researchers found that those treated with AV optimization, both echocardiography and SmartDelay, did significantly better with respect to the primary endpoint compared to those treated with the preset program.

The results showed the importance of large clinical trials, Ellenbogen said.

“We should never assume that just because something makes sense from a physiologic point of view, or has been studied in a small numbers of patients, that we should automatically expect that it will make a big impact on patient outcomes,” he said.

Co-authors are Michael R. Gold, M.D., Ph.D.; Timothy E. Meyer, Ph.D.; Ignacio Fernandez Lozano, M.D.; Suneet Mittal, M.D.; Alan D. Waggoner, M.H.S.; Bernd Lemke, M.D.; Jagmeet P. Singh, M.D.; Francis G. Spinale, M.D., Ph.D.; Jennifer E. Van Eyk, Ph.D.; Jeffrey Whitehill, M.D.; Stanislav Weiner, M.D.; Maninder Bedi, M.D.; and Kenneth M. Stein, M.D. Author disclosures are on the abstract.

Boston Scientific of Natick, Mass., funded the study.

###

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.

NR10-1171 (SS10/LBCT II-Ellenbogen)

(Note: Actual presentation time: 11:07 a.m. CT, Monday, Nov. 15, 2010)

Additional resources:

•To learn more about the diagnosis and treatment of heart failure, visit www.heart.org/heartfailure.
•Multimedia resources (animation, audio, video and images) are available in our newsroom at Scientific Sessions 2010 - Multimedia.
•Stay up to date on the latest news from American Heart Association scientific meetings, including Scientific Sessions 2010, by following us at www.twitter.com/heartnews. We will be tweeting from the conference using hashtag #AHA10News.


Standard pacing therapy regulates heart pumping as well as costly tailored methods